TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$51 Million

Trillium Therapeutics

Follow-on Offering

Bookrunner, April 2015

Trillium Therapeutics
Trillium Therapeutics Inc is a Canadian clinical stage immuno-oncology company which is engaged in developing therapies for the treatment of cancer. The lead program of the company is TTI-621 which is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. The company has proprietary medicinal chemistry platform, using fluorine chemistry which permits the creation of new chemical entities with pharmacological properties. The company operates through the single segment being Research and development of therapies for the treatment of cancer.